Results 21 to 30 of about 55,251 (223)
Immune-Complex Mimics as a Molecular Platform for Adjuvant-Free Vaccine Delivery [PDF]
, 2013 Protein-based vaccine development faces the difficult challenge of finding robust yet non-toxic adjuvants suitable for humans. Here, using a molecular engineering approach, we have developed a molecular platform for generating self-adjuvanting immunogens
A Demissie +68 more
core +8 more sources
Биопрепараты: Профилактика, диагностика, лечение, 2022 To date, the Bacillus Calmette–Guérin (BCG) vaccine has been the only medicinal product for active mass childhood immunisation against tuberculosis in the Russian Federation.
D. T. Levi +5 more
doaj +1 more source
Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. [PDF]
PLoS ONE, 2009 Recombinant adenovirus-vectored (Ad) tuberculosis (TB) vaccine platform has demonstrated great potential to be used either as a stand-alone or a boost vaccine in murine models.
Zhou Xing +5 more
doaj +1 more source
Tuberculosis vaccine: pipeline approaches and future prospective [PDF]
, 2011 Tuberculosis (TB), despite anti-mycobacterial therapies and vaccine, is a deadly infectious disease with about 12 million incident cases worldwide. Existing Bacillus Calmette-Guérin (BCG) vaccine is unquestionably inexpensive, safe and effective ...
Ankita Singh +2 more
core +2 more sources
Annals of Saudi Medicine, 2012 BACKGROUND AND OBJECTIVES: Bacille Calmette-Guérin (BCG) vaccination is part of the expanded program of vaccination in Saudi Arabia. Lymphadenitis is the most common complication of the BCG vaccine.
Abdulkarim Abdullah Alrabiaah +4 more
doaj +1 more source
Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy. [PDF]
PLoS Neglected Tropical Diseases, 2016 Buruli ulcer (BU) vaccine design faces similar challenges to those observed during development of prophylactic tuberculosis treatments. Multiple BU vaccine candidates, based upon Mycobacterium bovis BCG, altered Mycobacterium ulcerans (MU) cells ...
Bryan E Hart, Sunhee Lee
doaj +1 more source
Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges. [PDF]
, 2019 Introduction: Tuberculosis (TB) remains a major health threat and it is now clear that the current vaccine, BCG, is unable to arrest the global TB epidemic. A new vaccine is needed to either replace or boost BCG so that a better level of protection could
Barclay WR +8 more
core +1 more source
Microbiology Spectrum, 2014 ABSTRACT BCG is the collective name for a family of live attenuated strains of Mycobacterium bovis that are currently used as the only vaccine against tuberculosis (TB). There are two major reasons for studying the genome of these organisms: (i) Because they are attenuated, BCG vaccines provide a window ...
Vanessa, Tran, Jun, Liu, Marcel A, Behr
openaire +2 more sources
Sleeping Beauty and the Story of the Bacille Calmette-Guérin Vaccine
mBio, 2016 Mycobacterium bovis BCG is the only available vaccine for protection against tuberculosis (TB). While BCG protects children from severe disease, it has little impact on pulmonary disease in adults. A recombinant BCG vaccine BCG ΔureC::hly (strain VPM1002)
Helen A. Fletcher
doaj +1 more source
Vaccines, 2021 Mycobacterium bovis bacillus Calmette–Guérin (BCG) is the only live attenuated vaccine available against tuberculosis. The first BCG vaccination was done exactly 100 years ago, in 1921.
Stefan Panaiotov +5 more
doaj +1 more source